TABLE 1.
Comparative performance levels of the LIPS assay, Western blot analysis, and the Plexus immunoassay for serologic diagnosis of HSV infectiona
| Assays and infection group | % (no. of samples detected/no. positive)
|
|
|---|---|---|
| Sensitivity | Specificity | |
| Western blot vs Plexus for HSV-1 (gG1) | ||
| Uninfected | 100 (14/14) | |
| HSV-1 | 100 (13/13) | |
| HSV-2 | 100 (14/14) | |
| HSV-1/2 | 75 (9/12) | |
| LIPS vs Western blot for HSV-1 (gG1) | ||
| Uninfected | 100 (14/14) | |
| HSV-1 | 100 (13/13) | |
| HSV-2 | 93 (13/14) | |
| HSV-1/2 | 83 (10/12) | |
| LIPS vs Plexus for HSV-1 (gG1) | ||
| Uninfected | 100 (14/14) | |
| HSV-1 | 100 (13/13) | |
| HSV-2 | 93 (13/14) | |
| HSV-1/2 | 92 (11/12) | |
| Western blot vs Plexus for HSV-2 (gG2) | ||
| Uninfected | 93 (13/14) | |
| HSV-1 | 100 (13/13) | |
| HSV-2 | 100 (14/14) | |
| HSV-1/2 | 100 (12/12) | |
| LIPS vs Western blot for HSV-2 (gG2) | ||
| Uninfected | 100 (14/14) | |
| HSV-1 | 100 (13/13) | |
| HSV-2 | 100 (14/14) | |
| HSV-1/2 | 100 (12/12) | |
| LIPS vs Plexus for HSV-2 (gG2) | ||
| Uninfected | 93 (13/14) | |
| HSV-1 | 100 (13/13) | |
| HSV-2 | 100 (14/14) | |
| HSV-1/2 | 100 (12/12) | |
a
For LIPS assays, the cutoff limit for calculating sensitivity and specificity for each antigen was derived from the mean for the 14 uninfected samples plus 5 SD.